Nathan Pennell, Professor at Cleveland Clinic, shared a post Bristol Myers Squibb on LinkedIn, adding:
“We have come so far just in my career, with more people than ever surviving lung cancer through amazing achievements in prevention, screening, and treatment. However, it remains the deadliest cancer (by far) and there is still a lot to do.
I sat down with Christine M. Lovly, MD, PhD, FASCO and Tania Small, MD and discussed how far we’ve come and what excites us in the near future, with a great discussion ranging from lung cancer stigma and access, screening and AI nodule detection, to molecular testing and ctDNA, to the next generation of therapeutic modalities that could change the course of this deadliest of diseases.”
Quoting Bristol Myers Squibb‘s post:
“Nearly 70% of lung cancers are still diagnosed at an advanced stage, but extraordinary science is now giving some patients years of life back.
On the latest episode of DoctoRx Unscripted, Tania Small, MD, our head of Medical Affairs, sits down with Dr. Nate Pennell and Dr. Christine Lovly – two of the country’s leading thoracic oncologists – for an unfiltered conversation on what’s defining the next era of lung cancer care.
Together, they explore innovations transforming the field, including:
- Molecular profiling and biomarker-driven therapy;
- Liquid biopsy and ctDNA testing;
- AI-assisted detection and radiomics; and
- Next-generation immunotherapies.
Watch the full episode to see how these advances are reshaping care and to learn what it will take to bring them to every patient.”
Other articles about Lung Cancer on OncoDaily.